

Index to volume 61

Author index

- A**
- Abiose AK, Grossmann M, Tangphao O, Hoffman BB, Blaschke TF. Chloroquine-induced venodilation in human hand veins. 1997;61:677-83
- Agneter E (see Schmetterer et al). 1997;61:583-95
- Akkila J (see Ukkonen et al). 1997;61:596-607
- Amantea MA, Forrest A, Northfelt DW, Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. 1997;61:301-11
- Amidon GL (see Cheng et al). 1997;61:531-43
- Amit O (see Goldberg et al). 1997;61:59-69
- Arnold JMO (see Rau et al). 1997;61:401-9
- Arranto AJ (see Sotaniemi et al). 1997;61:331-9
- B**
- Backman JT (see Villikka et al). 1997;61:8-14
- Bailey DG (see Rau et al). 1997;61:401-9
- Baldassarre D, Mores N, Colli S, Pazzucconi F, Sirtori CR, Tremoli E. Platelet α_2 -adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation. 1997;61:684-91
- Barel S, Yagen B, Schurig V, Soback S, Pisani F, Perucca E, Bialer M. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. 1997;61:442-9
- Becker T (see Gleiter et al). 1997;61:669-76
- Bequemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. 1997;61:619-27
- Bellissant E, Duhamel JF, Guillot M, Pariente-Khayat A, Olive G, Pons G. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. 1997;61:377-84
- Bend JR (see Rau et al). 1997;61:401-9
- Benowitz NL. A message from the president: come to the ASCPT/ASPET meeting in San Diego March 5-8, 1997. 1997;61:100
- (see Zevin et al). 1997;61:649-54
- Berns JS (see Ermer et al). 1997;61:312-8
- Bialer M (see Barel et al). 1997;61:442-9
- Billard V, Gambus PL, Chamoun N, Stanski DR, Shafer SL. A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect. 1997;61:45-58
- Biollaz J (see Goldberg et al). 1997;61:59-69
- Blake DS (see Cheng et al). 1997;61:531-43
- Blaschke TF (see Abiose et al). 1997;61:677-83
- Boni JP (see Ermer et al). 1997;61:312-8
- Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. 1997;61:544-53
- Botto A (see De Lepeleire et al). 1997;61:83-92
- Breiteneder H (see Schmetterer et al). 1997;61:583-95
- Brøsen K (see Madsen et al). 1997;61:319-24
- Brown NJ, Ray WA, Snowden M, Griffin MR. Race and angioedema. 1997;61:700 (Letter reply)
- (see Stein et al). 1997;61:662-8
- Brunner HR (see Goldberg et al). 1997;61:59-69
- Burghart P (see Ermer et al). 1997;61:312-8
- Burkhart GA. Race and angioedema. 1997;61:700 (Letter)

January, pp. 1-136; February, pp. 137-274; March, pp. 275-394; April, pp. 395-502; May, pp. 503-612; June, pp. 613-716. Index to the ASCPT meeting abstracts is located in the February issue.

- , Sevka MJ, Temple R, Honig PK. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. 1997;61:93-6
- Burris JF. Publication and proprietary information. 1997;61:494-5 (Letter)

- C**
- Campbell P (see Stein et al). 1997;61:662-8
- Canfield CJ (see Hussein et al). 1997;61:518-30
- Carel BJ (see Borin et al). 1997;61:544-53
- Carides A (see Goldberg et al). 1997;61:59-69
- Carithers RL Jr (see Chien et al). 1997;61:24-34
- Carlson MG (see Stein et al). 1997;61:662-8
- Carver PL (see Cheng et al). 1997;61:531-43
- Cavanaugh JM (see Karol et al). 1997;61:450-8
- Cevallos WH (see Ermer et al). 1997;61:312-8
- Chambers JH (see Borin et al). 1997;61:544-53
- Chamoun N (see Billard et al). 1997;61:45-58
- Charles B (see Lee et al). 1997;61:628-40
- Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. 1997;61:531-43
- Chien JY, Peter RM, Nolan CM, Wartell C, Slattery JT, Nelson SD, Carithers RL Jr, Thummel KE. Influence of polymorphic *N*-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. 1997;61:24-34
- Chikazawa S (see Okumura et al). 1997;61:509-17
- Chiou R (see Goldberg et al). 1997;61:59-69
- Christ DD (see Goldberg et al). 1997;61:59-69
- Cohen RM (see Ermer et al). 1997;61:312-8
- Colli S (see Baldassarre et al). 1997;61:684-91
- Cox SR (see Cheng et al). 1997;61:531-43

- D**
- Dab I (see Špičák et al). 1997;61:325-30
- Darbar D, Dell'Orto S, Mörike K, Wilkinson GR, Roden DM. Dietary salt increases first-pass elimination of oral quinidine. 1997;61:292-300
- DeCleene S (see Ermer et al). 1997;61:312-8
- Decramer M (see De Lepeleire et al). 1997;61:83-92
- De Lepeleire I, Reiss TF, Rochette F, Botto A, Zhang J, Kundu S, Decramer M. Montelukast causes prolonged, potent leukotriene D_4 -receptor antagonism in the airways of patients with asthma. 1997;61:83-92
- Dell'Orto S (see Darbar et al). 1997;61:292-300
- de Longueville M (see Špičák et al). 1997;61:325-30
- DePalma RL (see Modell et al). 1997;61:476-87
- Desager JP (see Špičák et al). 1997;61:325-30
- Diasio RB (see Yan et al). 1997;61:563-73
- Dixon R (see Frye et al). 1997;61:15-23
- Domino EF, Ni LS, Zhang H. Effects of tobacco smoking on human ocular smooth pursuit. 1997;61:349-59
- , —, —. Effects of tobacco smoking on human ocular smooth pursuit (1997;61:349-59). 1997;61:627 (Correction)
- Drug Utilization Research Group. Multicenter study on self-medication and self-prescription in six Latin American countries. 1997;61:488-93
- Duhamel JF (see Bellissant et al). 1997;61:377-84

- E**
- Eaves J (see Hussein et al). 1997;61:518-30
- Eichelbaum M (see Mikus et al). 1997;61:459-66
- Eichler HG (see Schmetterer et al). 1997;61:583-95
- Ermer JC, Boni JP, Cevallos WH, DeCleene S, Burghart P, Rudnick MR, Fruncillo RJ, Berns JS, Cohen RM. Bromfenac disposition in patients with impaired kidney function. 1997;61:312-8
- Evans BK (see Green et al). 1997;61:340-8

F

- Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients. 1997;61:416-28
 Feyerabend C (see Green et al). 1997;61:340-8
 Findl O (see Schmetterer et al). 1997;61:583-95
 Flenady V (see Lee et al). 1997;61:628-40
 Forrest A (see Amantea et al). 1997;61:301-11
 Foss JF (see Yuan et al). 1997;61:467-75
 Foulds G (see Luke and Foulds). 1997;61:641-8
 Freimuth WW (see Borin et al). 1997;61:544-53
 Freudenthaler S (see Gleiter et al). 1997;61:669-76
 Fruncillo RJ (see Ermer et al). 1997;61:312-8
 Frye RF, Matzke GR, Schade R, Dixon R, Rabinovitz M. Effects of liver disease on the disposition of the opioid antagonist nalmeferene. 1997;61:15-23
 Fuller GS (see Green et al). 1997;61:340-8
 Funck-Brentano C (see Becquemont et al). 1997;61:619-27
 Furtek CI (see Goldberg et al). 1997;61:59-69

G

- Gagnon S (see Borin et al). 1997;61:544-53
 Gambus PL (see Billard et al). 1997;61:45-58
 Gelfand RA (see Harris et al). 1997;61:385-9
 Gerber N (see Iatsimirskaja et al). 1997;61:554-62
 Gleiter CH, Becker T, Schreeb KH, Freudenthaler S, Gundert-Remy U. Fenoterol but not dobutamine increases erythropoietin production in humans. 1997;61:669-76
 Goldberg MR, Lo MW, Christ DD, Chiou R, Furtek CI, Amit O, Carides A, Biollaz J, Piguet V, Nussberger J, Brunner HR. DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. 1997;61:59-69
 Goldman P. Olestra: assessing its potential to interact with drugs in the gastrointestinal tract. 1997;61:613-8 (Commentary)
 Gramatté T (see Mikus et al). 1997;61:459-66
 Graselli U (see Schmetterer et al). 1997;61:583-95
 Green JT, Thomas GAO, Rhodes J, Evans BK, Russell MAH, Feyerabend C, Fuller GS, Newcombe RG, Sandborn WJ. Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. 1997;61:340-8
 Gries JM, Troconiz IF, Verotta D, Jacobson M, Sheiner LB. A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex. 1997;61:70-82
 Griffin MR (see Brown et al). 1997;61:700 (Letter reply)
 Groen EWJ (see Schwietert et al). 1997;61:360-76
 Grossmann M (see Abiose et al). 1997;61:677-83
 Guillot M (see Bellissant et al). 1997;61:377-84
 Gundert-Remy U (see Gleiter et al). 1997;61:669-76

H

- Harris WS, Windsor SL, Newton FA, Gelfand RA. Inhibition of cholesterol absorption with CP-148,623 lowers serum cholesterol in humans. 1997;61:385-9
 Harvengt C (see Špičák et al). 1997;61:325-30
 Haworth S (see Yan et al). 1997;61:563-73
 Hirschhorn W (see Morgan et al). 1997;61:35-44
 Höckerstedt K (see Tallgren et al). 1997;61:655-61
 Hoffman BB (see Abiose et al). 1997;61:677-83
 Hofmann U (see Mikus et al). 1997;61:459-66
 Honig PK (see Burkhardt et al). 1997;61:93-6
 Hulhoven R (see Špičák et al). 1997;61:325-30
 Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by *Plasmodium falciparum*. 1997;61:518-30
 Hutchinson DB (see Hussein et al). 1997;61:518-30

I

- Iatsimirskaja E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N, Koudriakova T. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. 1997;61:554-62
 Ishizaki T (see Sohn et al). 1997;61:574-82
 Iwakawa S (see Okumura et al). 1997;61:509-17

J

- Jacob P III (see Zevin et al). 1997;61:649-54
 Jacobson M (see Gries et al). 1997;61:70-82
 Jaillon P (see Becquemont et al). 1997;61:619-27
 Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. 1997;61:410-5
 Jonkman JHG (see Schwietert et al). 1997;61:360-76
 Jusko WJ (see Ferron et al). 1997;61:416-28

K

- Karol MD, Machinist JM, Cavanaugh JM. Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. 1997;61:450-8
 Katholi CR (see Modell et al). 1997;61:476-87
 Kauffman CA (see Cheng et al). 1997;61:531-43
 Kim HK (see Sohn et al). 1997;61:574-82
 Kita T (see Okumura et al). 1997;61:509-17
 Kivistö KT (see Villikka et al). 1997;61:8-14
 Klánová M (see Špičák et al). 1997;61:325-30
 Knuuti MJ (see Ukkonen et al). 1997;61:596-607
 Komada F (see Okumura et al). 1997;61:509-17
 Koudriakova T (see Iatsimirskaja et al). 1997;61:554-62
 Kundu S (see De Lepeleire et al). 1997;61:83-92
 Kwon JT (see Sohn et al). 1997;61:574-82

L

- Le Bot MA (see Becquemont et al). 1997;61:619-27
 Lee PC (see Yan et al). 1997;61:563-73
 Lee TC, Charles B, Steer P, Flenady V, Shearman A. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. 1997;61:628-40
 Lehtonen L (see Ukkonen et al). 1997;61:596-607
 Lewis LD, Smith BW, Mamourian AC. Delayed sequelae after acute overdoses or poisonings: cranial neuropathy related to ethylene glycol ingestion. 1997;61:692-9
 Lindgren L (see Tallgren et al). 1997;61:655-61
 Lloyd P (see Morgan et al). 1997;61:35-44
 Lo MW (see Goldberg et al). 1997;61:59-69
 Luke DR, Foulds G. Disposition of oral azithromycin in humans. 1997;61:641-8
 Lunn G. Publication and proprietary information. 1997;61:495 (Letter)

M

- Machinist JM (see Karol et al). 1997;61:450-8
 Madsen H, Rasmussen BB, Brøsen K. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. 1997;61:319-24
 Mamelok R (see Amantea et al). 1997;61:301-11
 Mamourian AC (see Lewis et al). 1997;61:692-9
 Marcus P, McCauley DL. Steroid therapy and H₂-receptor antagonists: pharmacoeconomic implications. 1997;61:503-8 (Commentary)
 Matzke GR (see Frye et al). 1997;61:15-23
 McCauley DL (see Marcus and McCauley). 1997;61:503-8 (Commentary)
 McCrary MM (see Yan et al). 1997;61:563-73
 Meyer KM (see Cheng et al). 1997;61:531-43
 Mikus G, Trausch B, Rodewald C, Hofmann U, Richter K, Gramatté T, Eichelbaum M. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. 1997;61:459-66
 Mishina EV (see Ferron et al). 1997;61:416-28
 Modell JD (see Modell et al). 1997;61:476-87
 Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. 1997;61:476-87
 Mores N (see Baldassarre et al). 1997;61:684-91
 Morgan JM, Palmisano M, Piraino A, Hirschhorn W, Spencer S, Prasad PP, Ortiz M, Lloyd P. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. 1997;61:35-44
 Mörike K (see Darbar et al). 1997;61:292-300
 Moss J (see Yuan et al). 1997;61:467-75

N

- Nägren K (see Ukkonen et al). 1997;61:596-607
 Nelson SD (see Chien et al). 1997;61:24-34

Neuvonen PJ (see Jalava et al). 1997;61:410-5
— (see Villikka et al). 1997;61:8-14
Newcombe RG (see Green et al). 1997;61:340-8
Newton FA (see Harris et al). 1997;61:385-9
Ni LS (see Domino et al). 1997;61:349-59
Nolan CM (see Chien et al). 1997;61:24-34
Northfelt DW (see Amantea et al). 1997;61:301-11
Nussberger J (see Goldberg et al). 1997;61:59-69

O

Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tanigawara Y. Genotyping of *N*-acetylation polymorphism and correlation with procainamide metabolism. 1997; 61:509-17
Olive G (see Bellissant et al). 1997;61:377-84
Olkkola KT (see Jalava et al). 1997;61:410-5
— (see Tallgren et al). 1997;61:655-61
— (see Villikka et al). 1997;61:8-14
Olsen SJ (see Yan et al). 1997;61:563-73
Ortiz M (see Morgan et al). 1997;61:35-44
Osinski J (see Yuan et al). 1997;61:467-75

P

Palmisano M (see Morgan et al). 1997;61:35-44
Pariente-Khayat A (see Bellissant et al). 1997;61:377-84
Pasanen M (see Sotaniemi et al). 1997;61:331-9
Pazzucconi F (see Baldassarre et al). 1997;61:684-91
Pelkonen O (see Sotaniemi et al). 1997;61:331-9
Perucca E (see Barel et al). 1997;61:442-9
Peter RM (see Chien et al). 1997;61:24-34
Piguet V (see Goldberg et al). 1997;61:59-69
Pincus T (see Stein et al). 1997;61:1-7 (Commentary)
Piraino A (see Morgan et al). 1997;61:35-44
Pisani F (see Barel et al). 1997;61:442-9
Pons G (see Bellissant et al). 1997;61:377-84
Prasad PP (see Morgan et al). 1997;61:35-44

R

Rabinovitz M (see Frye et al). 1997;61:15-23
Ragueneau I (see Becquemont et al). 1997;61:619-27
Rasmussen BB (see Madsen et al). 1997;61:319-24
Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. 1997;61:401-9
Ray WA (see Brown et al). 1997;61:700 (Letter reply)
Raymond R (see Yan et al). 1997;61:563-73
Reele SB. Publishing Summary Basis of Approval. 1997; 61:496 (Letter reply)
Reidenberg MM. Note from the Editor. 1997;61:496 (Letter)
— What should authors expect from the reviewers and the editors of *Clinical Pharmacology & Therapeutics*? 1997;61:497-8
Reiss TF (see De Lepeleire et al). 1997;61:83-92
Reuning RH (see Tzou et al). 1997;61:429-41
Rhodes J (see Green et al). 1997;61:340-8
Riche C (see Becquemont et al). 1997;61:619-27
Richter K (see Mikus et al). 1997;61:459-66
Rochette F (see De Lepeleire et al). 1997;61:83-92
Roden DM (see Darbar et al). 1997;61:292-300
Rodewald C (see Mikus et al). 1997;61:459-66
Roizen MF (see Yuan et al). 1997;61:467-75
Rudnick MR (see Ermer et al). 1997;61:312-8
Russell MAH (see Green et al). 1997;61:340-8

S

Sams RA (see Tzou et al). 1997;61:429-41
Sandborn WJ (see Green et al). 1997;61:340-8
Saraste M (see Ukkonen et al). 1997;61:596-607
Schade R (see Frye et al). 1997;61:15-23
Schmetterer L, Strenn K, Findl O, Breiteneder H, Grasseili U, Agneter E, Eichler HG, Wolzt M. Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. 1997;61:583-95
Schreeb KH (see Gleiter et al). 1997;61:669-76
Schurig V (see Barel et al). 1997;61:442-9

Schwietert HR, Groen EWJ, Sollie FAE, Jonkman JHG. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. 1997;61:360-76
Seppälä T (see Tallgren et al). 1997;61:655-61
Sevka MJ (see Burkhart et al). 1997;61:93-6
Shafer SL (see Billard et al). 1997;61:45-58
Shearman A (see Lee et al). 1997;61:628-40
Sheiner LB. Learning versus confirming in clinical drug development. 1997;61:275-91 (Commentary)
— (see Gries et al). 1997;61:70-82
Silverman HI. Publishing Summary Basis of Approval. 1997;61:495-6 (Letter)
Sirtori CR (see Baldassarre et al). 1997;61:684-91
Slattery JT (see Chien et al). 1997;61:24-34
Smith BW (see Lewis et al). 1997;61:692-9
Smith D (see Iatasmirskaja et al). 1997;61:554-62
Smith DE (see Cheng et al). 1997;61:531-43
Snowden M (see Brown et al). 1997;61:700 (Letter reply)
Soback S (see Barel et al). 1997;61:442-9
Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the 5-mephenytoin 4'-hydroxylation phenotype status. 1997;61:574-82
Sollie FAE (see Schwietert et al). 1997;61:360-76
Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. 1997;61:331-9
Spence JD. Drug interactions with grapefruit: Whose responsibility is it to warn the public? 1997;61:395-400 (Commentary)
— (see Rau et al). 1997;61:401-9
Spencer S (see Morgan et al). 1997;61:35-44
Špičák V, Dab I, Hulhoven R, Desager JP, Klánová M, de Longueville M, Harvengt C. Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. 1997;61:325-30
Stanski DR (see Billard et al). 1997;61:45-58
Steer P (see Lee et al). 1997;61:628-40
Stein CM, Brown N, Carlson MG, Campbell P, Wood AJJ. Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels. 1997;61:662-8
—, Wood AJJ, Pincus T. Implementation of multiple outpatient formularies: undesirable effects. 1997;61:1-7 (Commentary)
Stetson PL (see Cheng et al). 1997;61:531-43
Storozhuk E (see Iatasmirskaja et al). 1997;61:554-62
Strenn K (see Schmetterer et al). 1997;61:583-95

T

Tallgren M, Olkkola KT, Seppälä T, Höckerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. 1997; 61:655-61
Tangphao O (see Abiose et al). 1997;61:677-83
Tanigawara Y (see Okumura et al). 1997;61:509-17
Temple R (see Burkhart et al). 1997;61:93-6
Thomas GAO (see Green et al). 1997;61:340-8
Thummel KE (see Chien et al). 1997;61:24-34
Toledano A (see Yuan et al). 1997;61:467-75
Tran LT (see Rau et al). 1997;61:401-9
Tausch B (see Mikus et al). 1997;61:459-66
Tremoli E (see Baldassarre et al). 1997;61:684-91
Troconiz IF (see Gries et al). 1997;61:70-82
Tulebaev S (see Iatasmirskaja et al). 1997;61:554-62
Tyring SK (see Yan et al). 1997;61:563-73
Tzou MC, Reuning RH, Sams RA. Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease. 1997;61:429-41

U

Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehtonen P, Nägren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. 1997; 61:596-607
Utkin I (see Iatasmirskaja et al). 1997;61:554-62

V

- Verotta D (*see* Gries et al). 1997;61:70-82
Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ.
Triazolam is ineffective in patients taking rifampin. 1997;61:8-14
Voipio-Pulkki LM (*see* Ukkonen et al). 1997;61:596-607

W

- Wartell C (*see* Chien et al). 1997;61:24-34
Watkins PB (*see* Cheng et al). 1997;61:531-43
Weinryb I. Disclosure of analytical information in pharmacokinetic papers. 1997;61:494 (Letter)
Whitsett TL. A message from the Membership Committee Chairman. 1997;61:608
Wilkinson GR (*see* Darbar et al). 1997;61:292-300
Windsor SL (*see* Harris et al). 1997;61:385-9
Wolzt M (*see* Schmetterer et al). 1997;61:583-95
Wood AJJ. A message from the Scientific Program Committee Chairperson. 1997;61:702

- (*see* Stein et al). 1997;61:1-7 (Commentary)
—— (*see* Stein et al). 1997;61:662-8

Y

- Yagen B (*see* Barel et al). 1997;61:442-9
Yan J, Tying SK, McCrary MM, Lee PC, Haworth S, Raymond R, Olsen SJ, Diasio RB. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. 1997;61:563-73
Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J. The safety and efficacy of oral methylbuprenorphine in preventing morphine-induced delay in oral-cecal transit time. 1997;61:467-75

Z

- Zevin S, Jacob P III, Benowitz N. Cotinine effects on nicotine metabolism. 1997;61:649-54
Zhang H (*see* Domino et al). 1997;61:349-59
Zhang J (*see* De Lepeleire et al). 1997;61:83-92
Zimmerman JJ (*see* Ferron et al). 1997;61:416-28

Subject index

A

- Abacavir succinate**
Abacavir succinate (USAN List No. 392). 1997;61:500
- Abstracts**
Abstracts. 1997;61:137-274
- Acetaminophen**
Influence of polymorphic *N*-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid (Chien et al). 1997;61:24-34
- Acetylation**
Genotyping of *N*-acetylation polymorphism and correlation with procainamide metabolism (Okumura et al). 1997;61:509-17
- Acetyltransferases**
Influence of polymorphic *N*-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid (Chien et al). 1997;61:24-34
- Acquired immunodeficiency syndrome**
A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex (Gries et al). 1997;61:70-82
Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma (Amantea et al). 1997;61:301-11
- Adrenal cortex hormones**
Steroid therapy and H₂-receptor antagonists: pharmacoeconomic implications (Marcus and McCauley). 1997;61:503-8 (Commentary)
- Age factors**
Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions (Sotaniemi et al). 1997;61:331-9
- AIDS; see Acquired immunodeficiency syndrome**
- AIDS-related complex**
A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex (Gries et al). 1997;61:70-82
- Alatrofloxacin mesylate**
Alatrofloxacin mesylate (USAN List No. 390). 1997;61:97
- Alexomycin**
Alexomycin (USAN List No. 392). 1997;61:501
- Alfentanil**
A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect (Billard et al). 1997;61:45-58
- Alpha adrenergic receptors; see Receptors, adrenergic, alpha**
- American Board of Clinical Pharmacology**
1996 diplomates certified. 1997;61:14
- American Society for Clinical Pharmacology and Therapeutics**
Abstracts of annual meeting. 1997;61:137-274
Election of Officers and Committee Chairpersons for 1997-1998. 1997;61:701
Future meeting dates and sites of the ASCPT. 1997;61:702
Meeting program. 1997;61:101-36
A message from the Membership Committee Chairman (Whitsett). 1997;61:608
A message from the President: come to the ASCPT/ASPET meeting in San Diego March 5-8, 1997 (Benowitz). 1997;61:100
A message from the Scientific Program Committee Chairperson (Wood). 1997;61:702
New members. 1997;61:608-10

January, pp. 1-136; February, pp. 137-274; March, pp. 275-394; April, pp. 395-502; May, pp. 503-612; June, pp. 613-716. Index to the ASCPT meeting abstracts is located in the February issue.

American Society for Pharmacology and Experimental Therapeutics

A message from the president: come to the ASCPT/ASPET meeting in San Diego March 5-8, 1997 (Benowitz). 1997; 61:100

Amlintide

Amlintide (USAN List No. 392). 1997;61:500

Angiotensin II

DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan (Goldberg et al). 1997; 61:59-69
The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects (Morgan et al). 1997; 61:35-44

Antibiotics

Disposition of oral azithromycin in humans (Luke and Foulds). 1997;61:641-8

Antibiotics, macrolide

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents (Iatsimirskaia et al). 1997;61:554-62

Antifungal agents

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents (Iatsimirskaia et al). 1997;61:554-62

Antigens, CD4

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex (Gries et al). 1997;61:70-82

Antiglaucoma drugs; see Glaucoma

Antihypertensive agents

The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects (Morgan et al). 1997;61:35-44

Apnea

Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity (Lee et al). 1997;61:628-40

Arginine butyrate

Arginine butyrate (USAN List No. 391). 1997;61:391

Asthma

Montelukast causes prolonged, potent leukotriene D₄-receptor antagonism in the airways of patients with asthma (De Lepeleire et al). 1997;61:83-92

Atiprimod dihydrochloride

Atiprimod dihydrochloride (USAN List No. 391). 1997;61:392

Atovaquone

Population pharmacokinetics of atovaquone in patients with acute malaria caused by *Plasmodium falciparum* (Hussein et al). 1997;61:518-30

Azithromycin

Disposition of oral azithromycin in humans (Luke and Foulds). 1997;61:641-8

B

Bectumomab

Bectumomab (USAN List No. 392). 1997;61:502

Bentoquatam

Bentoquatam (USAN List No. 391). 1997;61:392

Books

Books received. 1997;61:394

Breath tests

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test (Cheng et al). 1997;61:531-43

Bromfenac

Bromfenac disposition in patients with impaired kidney function (Ermer et al). 1997;61:312-8

Bupropion

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline (Modell et al). 1997;61:476-87

C

Caffeine

Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity (Lee et al). 1997;61:628-40

Calcium

Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers (Ukkonen et al). 1997;61:596-607

CD4; see Antigens, CD4**Cedelizumab**

Cedelizumab (USAN List No. 392). 1997;61:501

Cetirizine

Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers (Špičák et al). 1997;61:325-30

Child

Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers (Špičák et al). 1997;61:325-30

Chloroquine

Chloroquine-induced venodilation in human hand veins (Abiose et al). 1997;61:677-83

Cholesterol

Inhibition of cholesterol absorption with CP-148,623 lowers serum cholesterol in humans (Harris et al). 1997;61:385-9

Clinical Pharmacology & Therapeutics

What should authors expect from the reviewers and the editors of *Clinical Pharmacology & Therapeutics*? (Reidenberg). 1997;61:497-8

Codeine

Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype (Mikus et al). 1997;61:459-66

Colitis, ulcerative

Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis (Green et al). 1997;61:340-8

Commentaries

Commentaries. 1997;61:1-7, 275-91, 395-400, 503-8, 613-8

Confirming versus learning

Learning versus confirming in clinical drug development (Sheiner). 1997;61:275-91 (Commentary)

Correction

Effects of tobacco smoking on human ocular smooth pursuit (Domino et al). 1997;61:349-59. 1997;61:627

Costs and cost analysis

Implementation of multiple outpatient formularies: undesirable effects (Stein et al). 1997;61:1-7 (Commentary)
Steroid therapy and H₂-receptor antagonists: pharmacoeconomic implications (Marcus and McCauley). 1997;61:503-8 (Commentary)

Cotinine

Cotinine effects on nicotine metabolism (Zevin et al). 1997;61:649-54

CP-148,623

Inhibition of cholesterol absorption with CP-148,623 lowers serum cholesterol in humans (Harris et al). 1997;61:385-9

Cranial nerves

Delayed sequelae after acute overdoses or poisonings: cranial neuropathy related to ethylene glycol ingestion (Lewis et al). 1997;61:692-9

Cytochrome P450

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions (Sotaniemi et al). 1997;61:331-9

Dietary salt increases first-pass elimination of oral quinidine (Darbar et al). 1997;61:292-300

Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype (Mikus et al). 1997;61:459-66

Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4 (Madsen et al). 1997;61:319-24

Influence of polymorphic *N*-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid (Chien et al). 1997;61:24-34

Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans (Becquemont et al). 1997;61:619-27

Triazolam is ineffective in patients taking rifampin (Villikka et al). 1997;61:8-14

D

Delavirdine

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate (Borin et al). 1997;61:544-53

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test (Cheng et al). 1997;61:531-43

Deltibant

Deltibant (USAN List No. 391). 1997;61:393

Diabetes

Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease (Tzou et al). 1997;61:429-41

Diet

Dietary salt increases first-pass elimination of oral quinidine (Darbar et al). 1997;61:292-300

Inhibition of cholesterol absorption with CP-148,623 lowers serum cholesterol in humans (Harris et al). 1997;61:385-9

Digoxin

Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease (Tzou et al). 1997;61:429-41

Dihydropyrimidine

The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster (Yan et al). 1997;61:563-73

Dobutamine

Fenoterol but not dobutamine increases erythropoietin production in humans (Gleiter et al). 1997;61:669-76

Doxorubicin

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma (Amantea et al). 1997;61:301-11

Drug evaluation

Learning versus confirming in clinical drug development (Sheiner). 1997;61:275-91 (Commentary)

Drug interactions

Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels (Stein et al). 1997; 61:662-8

Drug interactions with grapefruit: Whose responsibility is it to warn the public? (Spence). 1997;61:395-400 (Commentary)

Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance (Rau et al). 1997;61:401-9

Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans (Becquemont et al). 1997;61:619-27

Itraconazole greatly increases plasma concentrations and effects of felodipine (Jalava et al). 1997;61:410-5

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents (Iatsimirskaia et al). 1997;61:554-62

Olestra: assessing its potential to interact with drugs in the gastrointestinal tract (Goldman). 1997;61:613-8 (Commentary)

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate (Borin et al). 1997;61:544-53

Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin (Burkhart et al). 1997;61:93-6

Triazolam is ineffective in patients taking rifampin (Villikka et al). 1997;61:8-14

Drug metabolism

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions (Sotaniemi et al). 1997;61:331-9

Cotinine effects on nicotine metabolism (Zevin et al). 1997; 61:649-54

Genotyping of *N*-acetylation polymorphism and correlation with procainamide metabolism (Okumura et al). 1997;61:509-17

Metabolic disposition of lansoprazole in relation to the *S*-mephenytoin 4'-hydroxylation phenotype status (Sohn et al). 1997;61:574-82

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents (Iatsimirskaia et al). 1997;61:554-62

Drugs, non-prescription

Multicenter study on self-medication and self-prescription in six Latin American countries (Drug Utilization Research Group). 1997;61:488-93

DuP 532

DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan (Goldberg et al). 1997;61:59-69

E

Echocardiography

Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers (Ukkonen et al). 1997;61:596-607

Editors

What should authors expect from the reviewers and the editors of *Clinical Pharmacology & Therapeutics*? (Reidenberg). 1997;61:497-8

Electroencephalography

A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect (Billard et al). 1997;61:45-58

Emedastine difumarate

Emedastine difumarate (USAN List No. 393). 1997;61:611

Enema

Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis (Green et al). 1997;61:340-8

Epilepsy

Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy (Barel et al). 1997;61:442-9

Epinephrine

Platelet α_2 -adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation (Baldassarre et al). 1997;61:684-91

Erythromycin

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test (Cheng et al). 1997;61:531-43

Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin (Burkhart et al). 1997;61:93-6

Erythropoietin

Fenoterol but not dobutamine increases erythropoietin production in humans (Gleiter et al). 1997;61:669-76

Ethylene glycol

Delayed sequelae after acute overdoses or poisonings: cranial neuropathy related to ethylene glycol ingestion (Lewis et al). 1997;61:692-9

Eye

Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers (Schmetterer et al). 1997;61:583-95

Effects of tobacco smoking on human ocular smooth pursuit (Domino et al). 1997;61:349-59

F

Fananserin

Fananserin (USAN List No. 392). 1997;61:501

Felodipine

Itraconazole greatly increases plasma concentrations and effects of felodipine (Jalava et al). 1997;61:410-5

Fenoterol

Fenoterol but not dobutamine increases erythropoietin production in humans (Gleiter et al). 1997;61:669-76

Filaminast

Filaminast (USAN List No. 390). 1997;61:99

Fluoxetine

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline (Modell et al). 1997;61:476-87

Fluvoxamine

Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans (Becquemont et al). 1997;61:619-27

Food-drug interactions

Drug interactions with grapefruit: Whose responsibility is it to warn the public? (Spence). 1997;61:395-400 (Commentary)

Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance (Rau et al). 1997;61:401-9

Olestra: assessing its potential to interact with drugs in the gastrointestinal tract (Goldman). 1997;61:613-8 (Commentary)

Formularies

Implementation of multiple outpatient formularies: undesirable effects (Stein et al). 1997;61:1-7 (Commentary)

G

Gastroesophageal reflux

The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux (Bellissant et al). 1997;61:377-84

Gastrointestinal motility

Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype (Mikus et al). 1997;61:459-66

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time (Yuan et al). 1997;61:467-75

Gastrointestinal tract

Olestra: assessing its potential to interact with drugs in the gastrointestinal tract (Goldman). 1997;61:613-8 (Commentary)

Gastrointestinal transit

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time (Yuan et al). 1997;61:467-75

Genotype

Genotyping of *N*-acetylation polymorphism and correlation with procainamide metabolism (Okumura et al). 1997;61:509-17

Glaucoma

Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers (Schmetterer et al). 1997;61:583-95

Glyburide

Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels (Stein et al). 1997;61:662-8

Grapefruit juice

Drug interactions with grapefruit: Whose responsibility is it to warn the public? (Spence). 1997;61:395-400 (Commentary)

Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance (Rau et al). 1997;61:401-9

H

Hand

Chloroquine-induced venodilation in human hand veins (Abiose et al). 1997;61:677-83

Hemodynamics

Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers (Schmetterer et al). 1997;61:583-95

Hemoglobin crosfumaryl

Hemoglobin crosfumaryl (USAN List No. 394). 1997;61:705

Hepatic disease; see Liver diseases

Herpes zoster

The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster (Yan et al). 1997;61:563-73

Histamine antagonists

Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers (Špičák et al). 1997;61:325-30

Steroid therapy and H_2 -receptor antagonists: pharmacoeconomic implications (Marcus and McCauley). 1997;61:503-8 (Commentary)

HIV

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test (Cheng et al). 1997;61:531-43

Hypercholesterolemia

Inhibition of cholesterol absorption with CP-148,623 lowers serum cholesterol in humans (Harris et al). 1997;61:385-9

Platelet α_2 -adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation (Baldassarre et al). 1997;61:684-91

I

- Icopezil maleate**
Icopezil maleate (USAN List No. 393). 1997;61:611
- Imipramine**
Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4 (Madsen et al). 1997;61:319-24
- Immunoassays**
Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease (Tzou et al). 1997;61:429-41
- Infant**
Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers (Špičák et al). 1997;61:325-30
The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux (Bellissant et al). 1997;61:377-84
- Infant, newborn**
Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity (Lee et al). 1997;61:628-40
- Infection**
Population pharmacokinetics of atovaquone in patients with acute malaria caused by *Plasmodium falciparum* (Hussein et al). 1997;61:518-30
- Isoniazid**
Influence of polymorphic *N*-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid (Chien et al). 1997;61:24-34
- Itraconazole**
Itraconazole greatly increases plasma concentrations and effects of felodipine (Jalava et al). 1997;61:410-5

J

- Journal**
What should authors expect from the reviewers and the editors of *Clinical Pharmacology & Therapeutics*? (Reidenberg). 1997;61:497-8

K

- Kaposi's sarcoma; see Sarcoma, Kaposi's**
- Ketoconazole**
Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin (Burkhart et al). 1997;61:93-6
- Kidney**
Lansoprazole pharmacokinetics in subjects with various degrees of kidney function (Karol et al). 1997;61:450-8
- Kidney diseases**
Bromfenac disposition in patients with impaired kidney function (Ermer et al). 1997;61:312-8
Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease (Tzou et al). 1997;61:429-41
- Kidney transplantation**
Population pharmacokinetics of sirolimus in kidney transplant patients (Ferron et al). 1997;61:416-28

L

- Lansoprazole**
Lansoprazole pharmacokinetics in subjects with various degrees of kidney function (Karol et al). 1997;61:450-8
Metabolic disposition of lansoprazole in relation to the *S*-mephenytoin 4'-hydroxylation phenotype status (Sohn et al). 1997;61:574-82
- Latin America**
Multicenter study on self-medication and self-prescription in six Latin American countries (Drug Utilization Research Group). 1997;61:488-93
- Learning versus confirming**
Learning versus confirming in clinical drug development (Sheiner). 1997;61:275-91 (Commentary)
- Letters**
Disclosure of analytical information in pharmacokinetic papers (Weinryb). 1997;61:494
Note from the Editor (Reidenberg). 1997;61:496
Publication and proprietary information (Burris) (Letter); (Lunn) (Letter). 1997;61:494-5

- Publishing Summary Basis of Approval (Silverman) (Letter); (Ree) (Reply). 1997;61:495-6
Race and angioedema (Burkhart) (Letter); (Brown et al) (Reply). 1997;61:700

Leukotriene D₄; see SRS-A**Levofloxacin**

- Levofloxacin (USAN List No. 390). 1997;61:97

Levosimendan

- Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers (Ukkonen et al). 1997;61:596-607

Liver

- Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents (Iatsimirskaia et al). 1997;61:554-62

Liver diseases

- Effects of liver disease on the disposition of the opioid antagonist nalmefene (Frye et al). 1997;61:15-23
Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease (Tzou et al). 1997;61:429-41

Liver transplantation

- Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation (Tallgren et al). 1997;61:655-61

Losartan

- DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan (Goldberg et al). 1997;61:59-69

M

Macrolides; see Antibiotics, macrolide**Malaria**

- Population pharmacokinetics of atovaquone in patients with acute malaria caused by *Plasmodium falciparum* (Hussein et al). 1997;61:518-30

Marimastat

- Marimastat (USAN List No. 391). 1997;61:390

Menopause

- Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers (Schwiewert et al). 1997;61:360-76

Mephenytoin

- Metabolic disposition of lansoprazole in relation to the *S*-mephenytoin 4'-hydroxylation phenotype status (Sohn et al). 1997;61:574-82

Metesind glucuronate

- Metesind glucuronate (USAN List No. 391). 1997;61:392

Methylnaltrexone

- The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time (Yuan et al). 1997;61:467-75

Metoclopramide

- The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux (Bellissant et al). 1997;61:377-84

Microsomes, liver

- Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents (Iatsimirskaia et al). 1997;61:554-62

Midazolam

- A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect (Billard et al). 1997;61:45-58

Milodistim

- Milodistim (USAN List No. 393). 1997;61:612

Minalrestat

- Minalrestat (USAN List No. 394). 1997;61:703

Minoxidil

- Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels (Stein et al). 1997;61:662-8

Montelukast

- Montelukast causes prolonged, potent leukotriene D₄-receptor antagonism in the airways of patients with asthma (De Lepeleire et al). 1997;61:83-92

Morphine

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time (Yuan et al). 1997;61:467-75

Muplestim

Muplestim (USAN List No. 393). 1997;61:612

Myocardium

Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers (Ukkonen et al). 1997;61:596-607

N

Nalmefene

Effects of liver disease on the disposition of the opioid antagonist nalmefene (Frye et al). 1997;61:15-23

Napitane mesylate

Napitane mesylate (USAN List No. 391). 1997;61:391

Narcotics

Effects of liver disease on the disposition of the opioid antagonist nalmefene (Frye et al). 1997;61:15-23

Nelfinavir mesylate

Nelfinavir mesylate (USAN List No. 391). 1997;61:390

Neonate; see Infant, newborn

Nerelimomab

Nerelimomab (USAN List No. 393). 1997;61:612

Nicotine

Cotinine effects on nicotine metabolism (Zevin et al). 1997;61:649-54

Effects of tobacco smoking on human ocular smooth pursuit (Domino et al). 1997;61:349-59

Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis (Green et al). 1997;61:340-8

Nystagmus

Effects of tobacco smoking on human ocular smooth pursuit (Domino et al). 1997;61:349-59

O

Olestra

Olestra: assessing its potential to interact with drugs in the gastrointestinal tract (Goldman). 1997;61:613-8 (Commentary)

Omoconazole nitrate

Omoconazole nitrate (USAN List No. 394). 1997;61:704

Opioids; see Narcotics

Oprelvekin

Oprelvekin (USAN List No. 393). 1997;61:612

Osteoporosis, postmenopausal

Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers (Schwietert et al). 1997;61:360-76

Outpatients

Implementation of multiple outpatient formularies: undesirable effects (Stein et al). 1997;61:1-7 (Commentary)

Overdose

Delayed sequelae after acute overdoses or poisonings: cranial neuropathy related to ethylene glycol ingestion (Lewis et al). 1997;61:692-9

Oxycodone

Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation (Tallgren et al). 1997;61:655-61

P

Parathyroid hormones

Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers (Schwietert et al). 1997;61:360-76

Paroxetine

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline (Modell et al). 1997;61:476-87

Patient education

Drug interactions with grapefruit: Whose responsibility is it to warn the public? (Spence). 1997;61:395-400 (Commentary)

Perflenapent

Perflenapent (USAN List No. 394). 1997;61:704

Perflisopent

Perflisopent (USAN List No. 394). 1997;61:704

Phenotype

Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype (Mikus et al). 1997;61:459-66

Influence of polymorphic *N*-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid (Chien et al). 1997;61:24-34

Metabolic disposition of lansoprazole in relation to the *S*-mephenytoin 4'-hydroxylation phenotype status (Sohn et al). 1997;61:574-82

Plasmodium falciparum

Population pharmacokinetics of atovaquone in patients with acute malaria caused by *Plasmodium falciparum* (Hussein et al). 1997;61:518-30

Platelet aggregation

Platelet α_2 -adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation (Baldassarre et al). 1997;61:684-91

Poisoning

Delayed sequelae after acute overdoses or poisonings: cranial neuropathy related to ethylene glycol ingestion (Lewis et al). 1997;61:692-9

Population studies

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma (Amantea et al). 1997;61:301-11

Population pharmacokinetics of atovaquone in patients with acute malaria caused by *Plasmodium falciparum* (Hussein et al). 1997;61:518-30

Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity (Lee et al). 1997;61:628-40

Population pharmacokinetics of sirolimus in kidney transplant patients (Ferron et al). 1997;61:416-28

Positron emission tomography; see Tomography, emission-computed

Potassium

Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels (Stein et al). 1997;61:662-8

Pramlintide

Pramlintide (USAN List No. 392). 1997;61:501

Prescriptions, drug

Implementation of multiple outpatient formularies: undesirable effects (Stein et al). 1997;61:1-7 (Commentary)

Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin (Burkhart et al). 1997;61:93-6

Procainamide

Genotyping of *N*-acetylation polymorphism and correlation with procainamide metabolism (Okumura et al). 1997;61:509-17

Propofol

A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect (Billard et al). 1997;61:45-58

Pursuit, smooth

Effects of tobacco smoking on human ocular smooth pursuit (Domino et al). 1997;61:349-59

Q

Quetiapine fumarate

Quetiapine fumarate (USAN List No. 392). 1997;61:502

Quilostigmine

Quilostigmine (USAN List No. 394). 1997;61:704

Quinidine

Dietary salt increases first-pass elimination of oral quinidine (Darbar et al). 1997;61:292-300

R

Receptors, adrenergic, alpha

Platelet α_2 -adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation (Baldassarre et al). 1997;61:684-91

Recombinant human parathyroid hormone; see Parathyroid hormones**Renal disease; see Kidney diseases****Respiration**

Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation (Tallgren et al). 1997;61:655-61

Reviewers

Guest reviewers. 1997;61:499

What should authors expect from the reviewers and the editors of *Clinical Pharmacology & Therapeutics*? (Reidenberg). 1997;61:497-8

Rifabutin

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents (Iatsimirskaia et al). 1997;61:554-62

Rifampin

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate (Borin et al). 1997;61:544-53

Triazolam is ineffective in patients taking rifampin (Villikka et al). 1997;61:8-14

S

Safety

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time (Yuan et al). 1997;61:467-75

Salt

Dietary salt increases first-pass elimination of oral quinidine (Darbar et al). 1997;61:292-300

Sarcoma, Kaposi's

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma (Amantea et al). 1997;61:301-11

Sedoxantrone trihydrochloride

Sedoxantrone trihydrochloride (USAN List No. 391). 1997;61:391

Self medication

Multicenter study on self-medication and self-prescription in six Latin American countries (Drug Utilization Research Group). 1997;61:488-93

Sertraline

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline (Modell et al). 1997;61:476-87

Sex behavior

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline (Modell et al). 1997;61:476-87

Sirolimus

Population pharmacokinetics of sirolimus in kidney transplant patients (Ferron et al). 1997;61:416-28

Smoking; see also Nicotine

Effects of tobacco smoking on human ocular smooth pursuit (Domino et al). 1997;61:349-59

Smooth pursuit; see Pursuit, smooth**Sorivudine**

The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster (Yan et al). 1997;61:563-73

SRS-A

Montelukast causes prolonged, potent leukotriene D₄-receptor antagonism in the airways of patients with asthma (De Lepeleire et al). 1997;61:83-92

Steroids

Steroid therapy and H₂-receptor antagonists: pharmacoeconomic

implications (Marcus and McCauley). 1997;61:503-8 (Commentary)

Sulesomab

Sulesomab (USAN List No. 392). 1997;61:502

T

Tacrine

Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans (Becquemont et al). 1997;61:619-27

Terfenadine

Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance (Rau et al). 1997;61:401-9

Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin (Burkhart et al). 1997;61:93-6

Teriparatide

Teriparatide (USAN List No. 394). 1997;61:703

Tiagabine hydrochloride

Tiagabine hydrochloride (USAN List No. 394). 1997;61:705

Ticolubant

Ticolubant (USAN List No. 394). 1997;61:705

Tobacco; see also Nicotine

Effects of tobacco smoking on human ocular smooth pursuit (Domino et al). 1997;61:349-59

Toddler; see Child**Tomography, emission-computed**

Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers (Ukkonen et al). 1997;61:596-607

Triazolam

Triazolam is ineffective in patients taking rifampin (Villikka et al). 1997;61:8-14

U

Ulcerative colitis; see Colitis, ulcerative**United States Adopted Names Council**

Cumulative list of USANs for 1996. 1997;61:98-9

USAN Council. 1997;61:97-9, 390-3, 500-2, 611-2, 703-5

V

Valnoctamide

Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy (Barel et al). 1997;61:442-9

Valsartan

The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects (Morgan et al). 1997;61:35-44

Vasodilation

Chloroquine-induced venodilation in human hand veins (Abiose et al). 1997;61:677-83

Veins

Chloroquine-induced venodilation in human hand veins (Abiose et al). 1997;61:677-83

Ventilation

Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation (Tallgren et al). 1997;61:655-61

Z

Zalcitabine

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex (Gries et al). 1997;61:70-82

Zidovudine

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex (Gries et al). 1997;61:70-82

